LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Two New FDA Rulings Expand Integra’s Product Offerings
Spine

Two New FDA Rulings Expand Integra’s Product Offerings

October 20, 2012 2 min read Premium comments

Advertisement

Two New FDA Rulings Expand Integra’s Product Offerings
Courtesy of Integra Life Sciences
Secondary

Earlier this month, the Food and Drug Administration approved an expanded use for Integra LifeSciences Holdings Corporation’s Vu aPOD, an intervertebral body fusion device (IBD) for use in anterior lumbar fusion (ALIF) procedures. The new indication includes four points of fixation composed of two screws and a SpinPlate.

“Earlier this year the Vu aPOD™ Prime IBD entered its full market release with stand-alone indications, ” said Kirt Stephenson, president, U.S. Spine. “We’re pleased that with this additional indication, we can now provide surgeons with multiple fixation options to best meet their patients’ needs.”

As Integra’s October 9 release explained, “IBDs are designed to help provide stability for spinal fusion after a diseased lumbar disc is surgically removed. They are small, hollow spinal implants that are inserted into the intervertebral space to restore physiological disc height and allow fusion between vertebral bodies. These devices relieve pressure on the nerves and provide positive mechanical stabilization of the vertebrae. The graft window in the device is packed with bone and provides an environment in which natural bone growth can occur, which then enables fusion of the vertebral segments.”

Traditionally, surgeons use supplemental fixation to help hold the IBD in place. The Integra Vu aPOD Prime IBD features two zero-profile options utilizing two screws or two screws and a SpinPlate to help secure the IBD in its functional position, eliminating the need for supplemental fixation implants, and reducing the number of steps and implants required to perform an ALIF procedure.

“The Integra® Vu aPOD™ Prime IBD provides surgeons with an easy and safer approach when compared to other devices that have four points of fixation with four screws, and a very minimally invasive way to provide stability of the anterior lumbar spine, with no additional sharp objects introduced to the outside of the spine, ” said Jaideep Chunduri, M.D., a design surgeon from Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio. “It is often difficult to place screws laterally within the lumbar spine. Integra’s SpinPlate™, in conjunction with two screws, enables four-point fixation without significant retraction. Because the SpinPlate™ is also located within the middle of the device, and provides built-in fixation, there is no added risk in terms of blood loss or vascular tissue. “

New Bone Tip

Shortly after announcing its Vu aPOD news, Integra rolled out its latest device at the Chicago Congress of Neurological Surgeons. It is a bone tip for the CUSA NXT Ultrasonic Tissue Ablation System. The new bone tip, which has received FDA clearance, allows surgeons to use ultrasonic tissue ablation in procedures requiring precise, controlled bone removal near critical structures where the rotational motion of a drill or frictional heat could be a concern.

The tip features a working surface oriented towards the bottom surface of the tip, making it useful in situations where the surgical setting requires downward pressure for bone removal. “The orientation of the new tip will help neurosurgeons during cases when they are approaching the bone from above. The tip also generates less heat, which can be important in certain surgical procedures, ” said Bob Davis, President of Integra’s Neurosurgery business. The company reports that over 2, 000 centers now rely on the CUSA ultrasonic surgical ablation technology for a variety of procedures.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy